Skip to main content

Month: August 2024

Orthopedic Implants Market Set for 3.5% CAGR Surge, Reaching USD 32.92 Billion by 2031 | SkyQuest Technology

Westford, USA, Aug. 08, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that Global Orthopedic Implants Market will attain a value of USD 32.92 Billion by 2031, with a CAGR of 3.5% over the forecast period (2024-2031). Over the course of the projected period, a rapid expansion in the orthopaedic implant market is anticipated. Major competitors in the global market provide solutions that support broken bones and tissues, allowing the patient’s body to operate more normally. These orthopaedic implant options are significantly more in demand due to their many benefits, which include minimal discomfort, affordable price, and speedy recuperation. Download a detailed overview: https://www.skyquestt.com/sample-request/orthopedic-implants-market Browse in-depth TOC on the ” Orthopedic Implants Market “Pages – 219 Tables...

Continue reading

Gainsight Extends Leadership in Human-First AI with Strategic Acquisition of Staircase AI

Acquisition provides AI-generated insights from customer interactions across every channel, delivering instant value for revenue and post-sales leaders SAN FRANCISCO, Aug. 08, 2024 (GLOBE NEWSWIRE) — Gainsight, the world’s leading Customer Success platform, today announced that it has signed a definitive agreement to acquire Staircase AI, a privately held company based in Los Angeles, CA and Tel Aviv, Israel. With this acquisition, Staircase AI will become a new distinct offering in the company’s artificial intelligence (AI) portfolio. Gainsight is a leader in AI, launching the first-to-market AI solutions for Customer Success in 2021. Today, Gainsight AI offers over a dozen features including the new Gainsight Copilot, currently in beta. Trusted and actively used by over 500 customers, Gainsight AI securely leverages large language...

Continue reading

Icon Energy Corp. Announces the Acquisition of a Kamsarmax Dry Bulk Carrier

ATHENS, Greece, Aug. 08, 2024 (GLOBE NEWSWIRE) — Icon Energy Corp. (“Icon Energy” or the “Company”) (Nasdaq: ICON), an international shipping company that provides worldwide seaborne transportation services for dry bulk cargoes, announces that on August 2, 2024, it entered, through a separate wholly-owned subsidiary, into an agreement with an unaffiliated third-party to acquire a Kamsarmax dry bulk carrier, built in November 2007 in Japan, for a purchase price of $17.57 million. The Company expects to finance the purchase price of the vessel with a combination of cash on hand and borrowings under a new senior secured facility that the Company anticipates it will enter into prior to taking delivery of the vessel. The acquisition is subject to the satisfaction of certain customary closing conditions and is expected to be concluded...

Continue reading

Lincoln Educational Services Reports Double Digit Growth in Revenue and Student Starts During Second Quarter 2024

Conference Call Today at 10 a.m. ET PARSIPPANY, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) — Lincoln Educational Services Corporation (Nasdaq: LINC) today announced financial and operating results for the second quarter ended June 30, 2024, as well as recent business developments. Second Quarter 2024 Financial Highlights*Revenue grew 16.1% to $102.9 million Student starts increased 12.3%; 11.4% increase in quarter-end student population Net loss of $700,000 and Adjusted EBITDA of $6.2 million Total liquidity of more than $100 million; no debt outstanding New East Point, Georgia campus student starts to date exceeds full-year plan Raised outlook for full year Revenue; raised lower end of adjusted EBITDA, adjusted net income and student starts; reduced 2024 capital expenditures due to timing*Note: The highlighted financial results...

Continue reading

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Over 122,000 prescriptions for VOQUEZNA® products written by healthcare providers, launch to date, a 184% increase since last quarterly report Net revenues of $7.3 million reported for the second quarter 2024 compared to $1.9 million in the first quarter 2024, greater than a 280% increase VOQUEZNA (vonoprazan) tablets 10mg now FDA-approved and available to treat heartburn associated with Non-Erosive Gastroesophageal Reflux Disease (GERD) in adults – unlocking the entire GERD market of over 22 million diagnosed and annually treated patients Expansion of commercial coverage for VOQUEZNA tablets now includes over 116 million U.S. lives, an estimated 77% of total U.S. commercial lives Management to host conference call today, August 8, 2024, at 8:30 am ETFLORHAM PARK, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals,...

Continue reading

Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Received FDA Breakthrough Therapy Designation for atacicept in IgA Nephropathy (IgAN) Presented data from Phase 2b ORIGIN study at ERA24 Congress showing atacicept stabilized kidney function through 72 weeks and led to rapid reductions in hematuria Topline 96-week data from Phase 2b ORIGIN study expected in Q4 2024 On track to complete enrollment in pivotal Phase 3 ORIGIN 3 trial for primary endpoint in Q3 2024; topline data expected in Q2 2025BRISBANE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the second quarter ended June 30, 2024. “We continue to strengthen the...

Continue reading

Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update

Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) scheduled for September and BLA submission planned for 2H 2024 Enrollment of first patient in Phase 3 confirmatory trial of RP1 in advanced melanoma expected in Q3 2024 Protocol finalized for registration-directed study of RP2 in uveal melanoma with study initiation activities underwayWOBURN, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30, 2024 and provided a business update. “We have had a highly productive quarter as we gear up for the upcoming pre-BLA meeting with the FDA and prepare to enroll the first...

Continue reading

Perma-Fix Reports Financial Results and Provides Business Update for the Second Quarter of 2024

ATLANTA, Aug. 08, 2024 (GLOBE NEWSWIRE) — Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced financial results and provided a business update for the second quarter ended June 30, 2024. Mark Duff, President and CEO of the Company, commented, “Our second quarter performance remained weak due to ongoing government delays in waste shipments, awarding new task orders and procuring other projects. We also experienced an extended equipment failure at one of our facilities that adversely impacted our revenue and overall performance. Nevertheless, we believe that these are temporary issues. We are encouraged by the trends heading into Q3, driven by our increasing backlog and bidding activities along with progress we believe is being made on our long-term growth initiatives.” “In the past few months we...

Continue reading

Where Food Comes From, Inc. Reports 2024 Second Quarter and Six-Month Financial Results

Second Quarter Highlights – 2024 vs. 2023Verification and certification revenue up 10% to $5.3 million from $4.8 millionProduct sales decline 13% to $0.8 million from $0.9 millionTotal revenue up 4% to $6.4 million from $6.1 millionNet income down 8% to $489,000 from $532,000Diluted EPS flat at $0.09Adjusted EBITDA of $844,000 vs. $917,000Company buys back 33,347 shares of stock in second quarterSix Month Highlights – 2024 vs. 2023Verification and certification revenue up 13% to $9.7 million from $8.6 millionProduct sales decline 19% to $1.6 million from $1.9 millionTotal revenue up 5% to $12.0 million from $11.4 millionNet income increases 2% to $667,000 from $653,000Diluted EPS of $0.12 vs. $0.11Adjusted EBITDA essentially flat at $1.3 millionCash generated from operations increased to $1.9 million from...

Continue reading

Disc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update

Presented positive data for all three programs at the European Hematology Association (EHA) 2024 Congress; demonstrated potential efficacy for bitopertin in erythropoietic protoporphyria (EPP) and DISC-0974 in anemia of myelofibrosis (MF), as well as proof of mechanism in a Phase 1 study for DISC-3405 Plan to provide an update on regulatory interactions for bitopertin in EPP and DISC-0974 in anemia of MF in the second half of 2024 Strengthened financial position through an underwritten offering of common stock for $178 million in gross proceeds, ending Q2 with $501 million in cash, cash equivalents, and marketable securities that is expected to fund operations well into 2027WATERTOWN, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.